[go: up one dir, main page]

SG11202002157TA - Compositions and methods for lyophilization of bacteria or listeria strains - Google Patents

Compositions and methods for lyophilization of bacteria or listeria strains

Info

Publication number
SG11202002157TA
SG11202002157TA SG11202002157TA SG11202002157TA SG11202002157TA SG 11202002157T A SG11202002157T A SG 11202002157TA SG 11202002157T A SG11202002157T A SG 11202002157TA SG 11202002157T A SG11202002157T A SG 11202002157TA SG 11202002157T A SG11202002157T A SG 11202002157TA
Authority
SG
Singapore
Prior art keywords
lyophilization
bacteria
compositions
methods
listeria strains
Prior art date
Application number
SG11202002157TA
Inventor
David Fela
Anu Wallecha
Mike Grace
Melissa Gosse
Original Assignee
Advaxis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advaxis Inc filed Critical Advaxis Inc
Publication of SG11202002157TA publication Critical patent/SG11202002157TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/04—Preserving or maintaining viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y206/00—Transferases transferring nitrogenous groups (2.6)
    • C12Y206/01—Transaminases (2.6.1)
    • C12Y206/01021—D-Amino-acid transaminase (2.6.1.21), i.e. D-alanine aminotransferase/transaminase or D-aspartic aminotransferase/transaminase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y501/00—Racemaces and epimerases (5.1)
    • C12Y501/01—Racemaces and epimerases (5.1) acting on amino acids and derivatives (5.1.1)
    • C12Y501/01001—Alanine racemase (5.1.1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
SG11202002157TA 2017-09-19 2018-08-29 Compositions and methods for lyophilization of bacteria or listeria strains SG11202002157TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762560318P 2017-09-19 2017-09-19
PCT/US2018/048586 WO2019060115A1 (en) 2017-09-19 2018-08-29 Compositions and methods for lyophilization of bacteria or listeria strains

Publications (1)

Publication Number Publication Date
SG11202002157TA true SG11202002157TA (en) 2020-04-29

Family

ID=65809919

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202002157TA SG11202002157TA (en) 2017-09-19 2018-08-29 Compositions and methods for lyophilization of bacteria or listeria strains

Country Status (11)

Country Link
US (2) US11179339B2 (en)
EP (2) EP4527412A2 (en)
JP (2) JP7284156B2 (en)
KR (2) KR102748132B1 (en)
CN (1) CN111356760A (en)
AU (2) AU2018336988B2 (en)
CA (1) CA3075849A1 (en)
IL (2) IL312459A (en)
MX (2) MX2020003100A (en)
SG (1) SG11202002157TA (en)
WO (1) WO2019060115A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
MA41644A (en) 2015-03-03 2018-01-09 Advaxis Inc LISTERIA-BASED COMPOSITIONS INCLUDING A MINIGEN EXPRESSION SYSTEM CODING PEPTIDES, AND METHODS OF USE THEREOF
WO2018102584A1 (en) 2016-11-30 2018-06-07 Advaxis, Inc. Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof
SG11202002157TA (en) 2017-09-19 2020-04-29 Advaxis Inc Compositions and methods for lyophilization of bacteria or listeria strains
ES2941526T3 (en) * 2018-03-20 2023-05-23 Nat Res Council Canada A method for lyophilizing live vaccine strains of Francisella tularensis
CN110106114A (en) * 2019-05-10 2019-08-09 上海市计量测试技术研究院(中国上海测试中心、华东国家计量测试中心、上海市计量器具强制检定中心) A kind of freeze drying protectant and freeze-drying store method and application for Listeria monocytogenes standard substance
CN112048545B (en) * 2020-09-10 2022-11-18 上海创宏生物科技有限公司 Freeze-drying protective agent, PCR amplification reagent, freeze-drying method and application thereof
US20230407240A1 (en) * 2020-10-24 2023-12-21 Kula Bio, Inc. Minimal footprint high density fermentation of plant byproducts
CN113287601A (en) * 2021-05-20 2021-08-24 江苏康进医疗器材有限公司 A three-dimensional multi-chamber cell bag suitable for cryopreservation
WO2024086605A1 (en) * 2022-10-18 2024-04-25 Takeda Vaccines, Inc. Dengue vaccine formulation
WO2024102751A2 (en) * 2022-11-07 2024-05-16 Southwest Research Institute Lyophilized and stabilized live attenuated formulated vaccine against tularemia

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4205132A (en) 1978-07-17 1980-05-27 Microlife Technics, Inc. Lyophilization of bacteria
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5830702A (en) 1990-10-31 1998-11-03 The Trustees Of The University Of Pennsylvania Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response
US6941753B1 (en) 1991-07-09 2005-09-13 Hydro-Gear Limited Partnership Hydrostatic transmission
US6051237A (en) 1994-11-08 2000-04-18 The Trustees Of The University Of Pennsylvania Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector
US7794729B2 (en) 1994-11-08 2010-09-14 The Trustees Of The University Of Pennsylvania Methods and compositions for immunotherapy of cancer
US8114414B2 (en) * 1994-11-08 2012-02-14 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical cancer
US7662396B2 (en) 2001-03-26 2010-02-16 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
US8791237B2 (en) 1994-11-08 2014-07-29 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of non-hodgkins lymphoma
US8956621B2 (en) 1994-11-08 2015-02-17 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical dysplasia
US7820180B2 (en) 2004-09-24 2010-10-26 The Trustees Of The University Of Pennsylvania Listeria-based and LLO-based vaccines
US20070264279A1 (en) 1994-11-08 2007-11-15 Claudia Gravekamp Compositions and methods comprising a MAGE-b antigen
WO1998012332A1 (en) 1996-09-17 1998-03-26 Chiron Corporation Compositions and methods for treating intracellular diseases
US6099848A (en) 1997-11-18 2000-08-08 The Trustees Of The University Of Pennsylvania Immunogenic compositions comprising DAL/DAT double-mutant, auxotrophic, attenuated strains of Listeria and their methods of use
GB9726555D0 (en) 1997-12-16 1998-02-11 Smithkline Beecham Plc Vaccine
JP2003516360A (en) 1999-12-09 2003-05-13 カイロン コーポレイション Method of administering cytokine to central nervous system and lymphatic system
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
EP1303299B1 (en) 2000-03-29 2010-07-28 The Trustees of The University of Pennsylvania Use of prokaryotic pest-like peptides for enhancing immunogenicity of antigens
US6855320B2 (en) 2000-03-29 2005-02-15 The Trustees Of The University Of Pennsylvania Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity
US8771702B2 (en) 2001-03-26 2014-07-08 The Trustees Of The University Of Pennsylvania Non-hemolytic LLO fusion proteins and methods of utilizing same
US7700344B2 (en) 2001-03-26 2010-04-20 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
JP2005527240A (en) 2002-05-29 2005-09-15 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア Attenuated Listeria species and how to use them
EP1594560A4 (en) 2003-01-09 2007-06-06 Univ Pennsylvania COMPOSITIONS, METHODS AND KITS ENHANCING THE IMMUNOGENECITY OF A BACTERIAL VACCINE VECTOR
ES2382332T3 (en) 2003-02-06 2012-06-07 Aduro Biotech Attenuated listeria to enter non-phagocytic cells, vaccines comprising this listeria and methods of use thereof
US7855064B2 (en) 2004-08-13 2010-12-21 The Trustees Of The University Of Pennsylvania Antibiotic resistance free vaccines and methods for constructing and using same
EP2942391B1 (en) 2004-08-13 2018-05-23 The Trustees Of The University Of Pennsylvania Methods for constructing antibiotic resistance free vaccines
US7858097B2 (en) 2004-08-13 2010-12-28 The Trustees Of The University Of Pennsylvania Antibiotic resistance free Listeria strains and methods for constructing and using same
CA2584130A1 (en) * 2004-10-18 2006-04-27 Medimmune, Inc. High cell density process for growth of listeria
WO2007061848A2 (en) * 2005-11-17 2007-05-31 The Trustees Of The University Of Pennsylvania Methods for producing, growing, and preserving listeria vaccine vectors
US7935804B2 (en) 2006-03-01 2011-05-03 Aduro Biotech Engineered Listeria and methods of use thereof
US7665238B2 (en) 2006-04-03 2010-02-23 S.C. Johnson & Son, Inc. Air freshener with holder
KR101521123B1 (en) * 2006-05-28 2015-05-19 시플라 메드프로 리서치 앤드 디벨롭먼트 (피티와이) 엘티디 Probiotic strain and antimicrobial peptide derived therefrom
US8268326B2 (en) 2006-08-15 2012-09-18 The Trustees Of The University Of Pennsylvania Compositions comprising HMW-MAA and fragments thereof, and methods of use thereof
EP3284478A1 (en) 2006-08-15 2018-02-21 The Trustees of the University of Pennsylvania Compositions comprising hmw-maa and fragments thereof for treating cancer
WO2008130551A2 (en) 2007-04-16 2008-10-30 The Trustees Of The University Of Pennsylvania Antibiotic resistance free listeria strains and methods for constructing and using same
KR101557169B1 (en) 2007-05-18 2015-10-02 메디뮨 엘엘씨 Preservation of living materials by freeze-dried foam
US20120135033A1 (en) 2008-05-19 2012-05-31 Anu Wallecha Multiple delivery system for heterologous antigens
WO2009143167A2 (en) 2008-05-19 2009-11-26 Advaxis Dual delivery system for heterologous antigens
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
US20140234370A1 (en) 2009-11-11 2014-08-21 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors
US9084747B2 (en) 2009-11-11 2015-07-21 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of HER2/NEU over-expressing tumors
US20150366955A9 (en) 2009-11-11 2015-12-24 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors
US8795686B2 (en) 2008-11-07 2014-08-05 Serum Institute Of India Stable, dried rotavirus vaccine, compositions and process for preparation thereof
ES2637068T3 (en) 2009-03-04 2017-10-10 The Trustees Of The University Of Pennsylvania Compositions comprising angiogenic factors and methods of use thereof
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
US20110223187A1 (en) 2010-02-15 2011-09-15 Vafa Shahabi Live listeria-based vaccines for central nervous system therapy
US20110305724A1 (en) 2010-04-19 2011-12-15 Yvonne Paterson Immunotherapeutic, anti-tumorigenic compositions and methods of use thereof
US9226958B2 (en) 2010-10-01 2016-01-05 University Of Georgia Research Foundation, Inc. Use of Listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals
CA2829960A1 (en) 2011-03-11 2012-09-20 John Rothman Listeria-based adjuvants
AU2013232291B8 (en) 2012-03-12 2016-07-21 Advaxis, Inc. Suppressor cell function inhibition following listeria vaccine treatment
LT2800811T (en) 2012-05-25 2017-09-11 The Regents Of The University Of California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
US10954486B2 (en) 2012-08-20 2021-03-23 Chr. Hansen A/S Method for freeze drying a bacteria-containing concentrate
SG10201700916SA (en) 2012-12-27 2017-03-30 Aduro Biotech Inc Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof
CA2897062A1 (en) 2013-01-15 2014-07-24 Teva Pharmaceutical Industries Ltd. Lyophilization process
JP6230796B2 (en) 2013-03-08 2017-11-15 日清食品ホールディングス株式会社 Freeze-dried bacteria sample and production method thereof
RU2016136855A (en) 2014-02-18 2018-03-22 Адваксис, Инк. BIOMARKER-DIRECTED MULTI-PURPOSE IMMUNOTHERAPY
KR20240038103A (en) 2014-02-25 2024-03-22 어드박시스, 인크. Compositions and methods for the treatment of her2/neu over-expressing tumors
JP2017508797A (en) 2014-03-05 2017-03-30 アドバクシス， インコーポレイテッド Methods and compositions for increasing the ratio of T effector cells to regulatory T cells
BR112016024352A2 (en) 2014-04-24 2018-01-23 Advaxis, Inc. "recombinant listeria strain, recombinant listeria, pharmaceutical composition, and methods of inducing an immune response against a tumor or cancer in a human and listeria individual"
WO2015167748A1 (en) 2014-05-02 2015-11-05 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of her-2-positive cancers
JP2017522322A (en) 2014-07-18 2017-08-10 アドバクシス， インコーポレイテッド Listeria-based immunogenic compositions for eliciting anti-tumor responses
CA2955366A1 (en) 2014-07-18 2016-01-21 Advaxis, Inc. Recombinant listeria strain expressing heterologous antigen fusion proteins and methods of use thereof
EP3193921A4 (en) 2014-07-18 2018-04-25 Advaxis, Inc. Combination of a pd-1 antagonist and a listeria-based vaccine for treating prostate cancer
WO2016011320A1 (en) 2014-07-18 2016-01-21 Advaxis, Inc. Bivalent listeria-based delivery system of heterologous antigens
CN104469766A (en) 2014-07-28 2015-03-25 北京佰才邦技术有限公司 Terminal authentication method and device used in mobile communication system
CA2964764A1 (en) 2014-10-14 2016-04-21 The Trustees Of The University Of Pennsylvania Combination therapy for use in cancer therapy
MA41218A (en) 2014-12-19 2017-10-24 Advaxis Inc LISTERIA VACCINE COMBINATION WITH ANTI-OX40 OR ANTI-GITR ANTIBODIES
WO2016105510A2 (en) 2014-12-26 2016-06-30 Conjugon, Inc. Methods and compositions for growth, storage, and use of bacterial preparations for wound and surface treatments
US20160220652A1 (en) 2015-02-03 2016-08-04 Advaxis, Inc. Methods of using recombinant listeria vaccine strains in disease immunotherapy
WO2016126878A2 (en) 2015-02-03 2016-08-11 The Trustees Of The University Of Pennsylvania Listeria-based immunomodulation
WO2016126876A2 (en) 2015-02-03 2016-08-11 Advaxis, Inc. Listeria-based adjuvants
MA41644A (en) 2015-03-03 2018-01-09 Advaxis Inc LISTERIA-BASED COMPOSITIONS INCLUDING A MINIGEN EXPRESSION SYSTEM CODING PEPTIDES, AND METHODS OF USE THEREOF
WO2016154412A2 (en) 2015-03-26 2016-09-29 The Trustees Of The University Of Pennsylvania Combination of a pd-1 antagonist and a listeria based vaccine for treating pancreatic cancer
US20180104284A1 (en) 2015-05-13 2018-04-19 Advaxis, Inc. Immunogenic Listeria-Based Compositions Comprising Truncated Acta-Antigen Fusions And Methods Of Use Thereof
EP3302574A4 (en) 2015-05-26 2018-10-17 Advaxis, Inc. Personalized delivery vector-based immunotherapy and uses thereof
TW201717974A (en) 2015-06-24 2017-06-01 艾法西斯公司 Manufacturing device and method based on personalized delivery carrier immunotherapy
EP3350337A4 (en) * 2015-09-15 2019-04-03 Advaxis, Inc. METHOD FOR MANUFACTURING AN IMMUNOTHERAPEUTIC FORMULATION COMPRISING A RECOMBINANT LISTERIA STRAIN
WO2017048850A1 (en) 2015-09-15 2017-03-23 Advaxis, Inc. Listeria-based immunogenic compositions and methods of use thereof in cancer prevention and treatment
MX2018003352A (en) 2015-09-17 2018-08-15 Advaxis Inc Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapy.
CA3001702A1 (en) 2015-10-14 2017-04-20 Advaxis, Inc. Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapy
US20180325964A1 (en) 2015-11-20 2018-11-15 Advaxis, Inc. Manufacturing device and method of an immunotherapeutic formulation comprising a recombinant listeria strain
US20180360940A1 (en) 2015-12-16 2018-12-20 Advaxis, Inc. Listeria-based immunotherapy and methods of use thereof
CA3012829A1 (en) 2016-01-27 2017-08-03 Advaxis, Inc. Personalized delivery vector-based immunotherapy and uses thereof
CN109641945A (en) 2016-07-05 2019-04-16 阿德瓦希斯公司 The immunogenic composition and its application method based on Listeria comprising wilms' tumor proteantigen
EP3534944A4 (en) 2016-11-07 2020-07-01 Advaxis, Inc. Combination of listeria-based vaccine with anti-ctla-4 or anti-cd137 antibodies
WO2018102585A1 (en) 2016-11-30 2018-06-07 Advaxis, Inc. Personalized immunotherapy in combination with immunotherapy targeting recurrent cancer mutations
WO2018102584A1 (en) 2016-11-30 2018-06-07 Advaxis, Inc. Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof
WO2018129306A1 (en) 2017-01-05 2018-07-12 Advaxis, Inc. Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapy
WO2019006401A2 (en) 2017-06-30 2019-01-03 Advaxis, Inc. Listeria-based immunogenic compositions comprising heteroclitic wilms tumor protein antigens and methods of use thereof
SG11202002157TA (en) 2017-09-19 2020-04-29 Advaxis Inc Compositions and methods for lyophilization of bacteria or listeria strains
AU2018366131A1 (en) 2017-11-08 2020-05-28 Advaxis, Inc. Immunogenic heteroclitic peptides from cancer-associated proteins and methods of use thereof
WO2019157098A1 (en) 2018-02-06 2019-08-15 Advaxis, Inc. Compositions comprising a recombinant listeria strain and an anti-ccr8 antibody and methods of use
CN112074737A (en) 2018-03-09 2020-12-11 阿德瓦希斯公司 Compositions and methods for evaluating listeria strains for attenuation and infectivity
EP3785029A1 (en) 2018-04-27 2021-03-03 Advaxis, Inc. Compositions and methods for evaluating potency of listeria-based immunotherapeutics

Also Published As

Publication number Publication date
IL273255A (en) 2020-04-30
US20220062181A1 (en) 2022-03-03
AU2023233129A1 (en) 2023-10-12
WO2019060115A1 (en) 2019-03-28
US12239738B2 (en) 2025-03-04
US20200261369A1 (en) 2020-08-20
CN111356760A (en) 2020-06-30
KR20250008132A (en) 2025-01-14
JP7284156B2 (en) 2023-05-30
IL273255B1 (en) 2024-06-01
MX2020003100A (en) 2020-08-20
KR102748132B1 (en) 2025-01-02
JP2020533997A (en) 2020-11-26
JP7649344B2 (en) 2025-03-19
KR20200044982A (en) 2020-04-29
AU2018336988B2 (en) 2023-06-22
MX2024005641A (en) 2024-05-24
EP3684912A4 (en) 2021-04-14
EP3684912B1 (en) 2025-02-26
US11179339B2 (en) 2021-11-23
IL312459A (en) 2024-06-01
NZ762881A (en) 2024-03-22
CA3075849A1 (en) 2019-03-28
EP3684912A1 (en) 2020-07-29
IL273255B2 (en) 2024-10-01
JP2023096115A (en) 2023-07-06
AU2018336988A1 (en) 2020-04-16
EP4527412A2 (en) 2025-03-26

Similar Documents

Publication Publication Date Title
IL273255A (en) Compositions and methods for lyophilization of bacteria or listeria strains
IL287586A (en) Methods and compositions for enrichment of amplification products
PL3240403T3 (en) Microbial compositions and methods of use for benefiting plant growth and treating plant disease
EP3912630C0 (en) Methods and compositions for changing the composition of the skin microbiome using complex mixtures of bacterial strains
EP3268018A4 (en) Bacterial compositions and methods of use thereof
PT3220741T (en) Composition and kits for inhibition of pathogenic microbial infection and methods of using the same
HK1248531A1 (en) Immunomodulatory compositions and methods of use thereof
EP3108245A4 (en) Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
SG11201609793TA (en) Composition and method for stabilizing and maintaining the viability of hardy microorganisms
IL273433A (en) Compositions and methods for pathogen inactivation of platelets
ZA202004531B (en) Compositions containing thymohydroquinone and their method of preparation
HK1249515A1 (en) Methods and compositions for the prevention and treatment of hearing loss
EP3532644A4 (en) Methods and compositions for preserving bacteria
GB201600975D0 (en) Novel strain of probiotic bacteria and compositions and uses thereof
SG11201700006UA (en) Process for enhancing the viable counts of lactic acid bacteria and useful compositions thereof
EP3226873A4 (en) Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same
HK1250345A1 (en) Compositions comprising 15-oxo-epa or 15-oxo-dgla and methods of making and using same
HK1250205A1 (en) Human milk compositions and methods of making and using same
PL3284351T3 (en) Method of pasteurizing and/or sterilising particulate material
EP3341006A4 (en) Compositions and methods for the treatment of neurodamage
EP3253396A4 (en) Probiotic compositions and methods of use
SG11202003300WA (en) Compositions and methods for treatment of fibrosis
IL260181A (en) Compositions and methods of use of novel strains of lactobacillus fermentum
GB201511799D0 (en) Composition and methods of treatment
GB201621737D0 (en) Compositions and methods of treatment